Ignite Creation Date:
2024-07-17 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06466798
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-06-13
Brief Title:
Fourth Ventricular Administration of Immune Checkpoint Inhibitor Nivolumab and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma Ependymoma and Other CNS Malignancies
Sponsor:
Organization:
The University of Texas Health Science Center Houston
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
10
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: